* Norwegian Drug Delivery Platform Biotech operating within the Oslo Cancer Cluster * Notoriously volatile norwegian small cap with large amount of stock held by enthusiastic retail investor crowd. * Ongoing research collaboration with AstraZeneca recently concluded, longs betting on partnership deal incoming. * Stock typically rallies ahead of quarterly reports...
We are now in a trading range with support at 49,- and resistance at 53,- If we break down the next support is at 44,- and if we break up we can go fast to 64,-
Just broke up from a descending triangle. Met resistance at second previous high at 49,4 If we in the next few days manage to establish above 49,4, the 51,5 resistance should be easy to take out.
GOING down or just a break before upwards to ATH?
Norwegian biotech smoking hot atm
PCI Biotech: US patent granted for the vaccine technology (fimaVACC) in combination with cytokines Oslo (Norway), 21 January 2020 – PCI Biotech OSL:PCIB , a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with...
www.va.se finansavisen.no PCI Biotech OSL:PCIB is a biopharmaceutical company focusing on development and commercialisation of novel therapeutic solutions for improved treatment of cancer patients through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that can be used to unlock the...
PCI Biotech Holding OSL:PCIB stock has been consolidating in a trading range below last years 30 NOK shareprice rights issue of NOK 360 million. Positive market reaction to the latest quarterly report from the company, along with good coverage in magasines: www.tu.no (norwegian language) nordiclifescience.org (page 91-94) At the moment, the stock is...
27 kr nivået er et viktig nivå for aksjen
OSL:PCIB www.netfonds.no Oslo (Norway), 2 May 2019 . PCI Biotech ( OSL:PCIB ), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the final immune response results from the fima_Vacc_ Phase I study in healthy volunteers indicate a clear enhancement of both CD8 and CD4...
Kursen testet taket i 6mnd konsoliderings range. Salgs presset kan tyde på at kursen må etablere en høyere base for å bryte gjennom. * Volumet har tatt seg opp * RSI ser bra ut Ser etter inngang ved overbevisende brudd over 30kr
PCIBO in potential cup formation and at same time inverse head and shoulder, both pattern stands for Bullish view.